Loading
ZI
Zogenix, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 12 Aug 2021.
Zogenix, Inc.: what insiders have been doing
Zogenix, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). Nothing new has been filed by managers of Zogenix, Inc. in twelve months, the latest record being from 9 March 2022.
These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
20
Thresholds
n/a
Buy Volume
€439,583
4 ops. · all time
Sell Volume
€55,055
1 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2021FY ended December 2021 · cache
Income statement
RevenueUS$64.4M
Net income-US$195.8M-304.3% margin
Last declaration on 9 March 2022
Declarations20 total
25,022 sharesCommon StockSEC:0000899243-22-010297:0
8,016 sharesCommon StockSEC:0000899243-22-010316:0
3,027 sharesCommon StockSEC:0000899243-22-010299:0
605 sharesCommon StockSEC:0000899243-22-010293:0
32,567 sharesCommon StockSEC:0000899243-22-010303:0
92,806 sharesCommon StockSEC:0000899243-22-010289:0
2,500 sharesCommon StockSEC:0000899243-22-010309:0
17,156 sharesCommon StockSEC:0000899243-22-010286:0
584 sharesCommon StockSEC:0000899243-22-010288:0
16,606 sharesCommon StockSEC:0000899243-22-010301:0
41,000 sharesCommon StockSEC:0000899243-22-010294:0
1,250 sharesCommon StockSEC:0000899243-22-010312:0
1,250 shares@ US$12.0013.9% of flowCommon StockSEC:0001375151-22-000006:0
6,250 shares@ US$15.0486.1% of flowStock Option (Right to Buy)SEC:0001375151-22-000002:0
5,305 shares@ US$11.7244.1% of flowCommon StockSEC:0001375151-21-000102:0
10,000 shares@ US$14.829835.0% of flowCommon StockSEC:0001375151-21-000089:0
Canonical exit: 8 Nov 2021 (T+90)
3,500 shares0Common StockSEC:0001375151-21-000074:0
5,000 shares@ US$17.049555.9% of flowCommon StockSEC:0001375151-21-000072:0
Canonical exit: 30 Aug 2021 (T+90)
584 shares@ US$17.07100.0% of flowCommon StockSEC:0001375151-21-000071:0
Canonical exit: 30 Aug 2021 (T+90)
15,000 shares@ US$19.033165.0% of flowCommon StockSEC:0001375151-21-000047:0
Canonical exit: 8 Aug 2021 (T+90)
20 of 20 declarations
About Zogenix, Inc.
Zogenix, Inc. was a U.S.-based biopharmaceutical company listed on the American NASDAQ market under the ticker ZGNX and headquartered in the United States, with principal offices in Emeryville, California. The company was founded in 2006 as SJ2 Therapeutics, Inc. and renamed Zogenix later that year. Its core strategy was to research, develop, and commercialize therapies for rare diseases, with a strong emphasis on difficult-to-treat pediatric epilepsy and other high-unmet-need neurological disorders. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1375151/000137515122000015/zgnx-20211231.htm?utm_source=openai))
From an operating standpoint, Zogenix was built around two main programs. The first and most important was FINTEPLA, an oral fenfluramine solution that became the company’s lead commercial asset. The second was MT1621, an investigational therapy for thymidine kinase 2 deficiency (TK2d), a rare and potentially life-threatening mitochondrial depletion disorder. Zogenix’s portfolio was therefore narrow but highly focused, reflecting a classic rare-disease biotech model: concentrate resources on a small number of clinically differentiated assets with meaningful regulatory and commercial potential. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1375151/000137515122000015/zgnx-20211231.htm?utm_source=openai))
Read moreShow less
In competitive terms, Zogenix operated in a specialized pharmaceutical niche where success depends less on broad primary-care scale and more on clinical efficacy, safety, regulatory exclusivity, physician adoption in expert centers, and payer acceptance. FINTEPLA’s positioning in rare epileptic syndromes such as Dravet syndrome and Lennox-Gastaut syndrome gave the company a differentiated profile within pediatric neurology. That made Zogenix a targeted rare-disease platform rather than a diversified commercial pharma company, with valuation driven primarily by pipeline execution and label expansion rather than by large-volume sales. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1375151/000137515122000015/zgnx-20211231.htm?utm_source=openai))
A major corporate milestone was Zogenix’s acquisition by UCB. UCB announced the deal in January 2022, launched a tender offer in February 2022, and completed the acquisition on March 7, 2022. The transaction was valued at $26.00 per share in cash at closing, plus a contingent value right tied to a potential European approval milestone for FINTEPLA in Lennox-Gastaut syndrome. As a result, Zogenix ceased to operate as an independent publicly traded company, and its principal asset, FINTEPLA, was folded into UCB’s broader epilepsy franchise. For investors looking at historical SEC insider activity, ZGNX is therefore best viewed as a legacy Nasdaq biopharma name whose public-market story ended with a strategic takeover. ([ucb.com](https://www.ucb.com/newsroom/press-releases/article/ucb-commences-tender-offer-to-acquire-zogenix-inc?utm_source=openai))
